Nathaniel Barnes, MD
Urology · Webster, TXNPI 1033119516
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $246,996 of the $331,377 with a category attached, or 74.5%. 37 manufacturers reported payments, led by Astellas Pharma US Inc at 56.6% of the total. Reporting peaked in 2024 at $95,729 and has fallen 50.8% since, to $47,120 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 630 payments — averaging $526.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$188K
- Sumitomo Pharma America, Inc.$98K
- Urovant Sciences Inc$26K
- Pfizer$14K
- Boston Scientific$2K
- Coloplast$910
- plus $3K from 31 others
What the payments were for
- Consulting fees$21,1406%
- Speaking & faculty fees$246,99675%
- Travel & lodging$47,89114%
- Food & beverage$15,0135%
- Education$3360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 250 | $187,610 |
| Sumitomo Pharma America, Inc. | 174 | $97,914 |
| Urovant Sciences Inc | 44 | $26,374 |
| Pfizer | 53 | $14,084 |
| Boston Scientific | 23 | $1,855 |
| Coloplast | 13 | $910 |
| Agiliti Surgical, Inc. | 4 | $323 |
| Dornier Medtech America, Inc | 2 | $235 |
| Astellas Pharma Global Development | 4 | $194 |
| Teleflex LLC | 4 | $182 |
| Neotract Inc. | 2 | $166 |
| Olympus America Inc. | 3 | $162 |
| AbbVie | 8 | $159 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $141 |
| Novo Nordisk | 1 | $116 |
| Myovant Sciences Inc. | 4 | $99 |
| Seagen Inc. | 1 | $96 |
| Bayer | 3 | $92 |
| Axonics, Inc. | 3 | $67 |
| Laborie Medical Technologies Corp. | 3 | $67 |
| Progenics Pharmaceuticals, Inc. | 2 | $62 |
| Antares Pharma, Inc. | 3 | $61 |
| Johnson & Johnson | 3 | $49 |
| 180 Medical, Inc. | 2 | $46 |
| Medtronic(2 entities) | 2 | $41 |
| Tolmar Pharmaceuticals, Inc. | 2 | $39 |
| Acerus Pharmaceuticals Corporation | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Ambu Inc. | 1 | $26 |
| Healthtronics Stone Solutions, LLC | 1 | $25 |
| Cook Medical LLC | 1 | $19 |
| RGH Enterprises LLC | 1 | $19 |
| Procept Biorobotics Corporation | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$155,239
- GEMTESA$113,237
- MYRBETRIQ$25,714
- ORGOVYX$750
- SPEEDICATH$481
- LithoVue$420
- UroLift$254
- Lithotripters & Accessories$235
- Sonablate HIFU$163
- Porges Coloplast$138
- Olympus Laser Devices$125
- Olympus Digital Flexible Ureteroscopes$125
- ShockPulse - SE$125
- VISERA ELITE$125
- GENERAL - THERAPIES$124
- Saxenda$116
- GENERAL BPH$101
How this compares
$331,377 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 29 | $418,792 |
| MyrbetriqMirabegron | 161 | $124,193 |
| ElmironPentosan Polysulfate Sodium | 35 | $68,373 |
| GemtesaVibegron | 52 | $37,693 |
| Silodosin | 133 | $17,173 |
| Mirabegron ErMirabegron | 15 | $13,824 |
| Solifenacin Succinate | 179 | $10,741 |
| Dutasteride | 148 | $4,714 |
| Testosterone Cypionate | 95 | $4,654 |
| Testosterone | 13 | $4,446 |
| Potassium Citrate ErPotassium Citrate | 36 | $4,263 |
| Tamsulosin Hcl | 193 | $2,712 |
| Fosfomycin Tromethamine | 12 | $2,071 |
| Estradiol | 19 | $1,811 |
| Finasteride | 125 | $1,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $187,610 | $542,985190 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $97,914 | $37,69352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Webster
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jonathan Clavell HernandezHouston$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.